What is the dosage of Yervoy?

Yervoy is available in 2 dosages, including 5 mg/ml Injection 40 ml and 5 mg/ml Injection 10 ml

What is Yervoy made of?

Yervoy contains ipilimumab which is a CTLA-4-directed Blocking Antibody

How is Yervoy administered?

Yervoy is administered as a Injectable

What is Yervoy mechanism of action?

Yervoy mechanism of action is CTLA-4-directed Antibody Interactions

Last Update: Oct, 21 2024

Yervoy(ipilimumab)

Yervoy 50 MG in 10 ML Injection

NO BOXED WARNING

Dosage & Administration

* Administer by intravenous infusion after dilution based upon recommended infusion rate for each indication. (2)
* Unresectable or Metastatic Melanoma:
* YERVOY 3 mg/kg every 3 weeks for a maximum of 4 doses. (2.2)
* YERVOY 3 mg/kg immediately following nivolumab 1 mg/kg on the same day, every 3 weeks for 4 doses. After completing 4 doses of the combination, administer nivolumab as a single agent as recommended in the Full Prescribing Information for nivolumab. (2.2)

* Adjuvant Treatment of Melanoma: YERVOY 10 mg/kg every 3 weeks for 4 doses, followed by 10 mg/kg every 12 weeks for up to 3 years. (2.2)
* Advanced Renal Cell Carcinoma: YERVOY 1 mg/kg immediately following nivolumab 3 mg/kg on the same day, every 3 weeks for 4 doses. After completing 4 doses of the combination, administer nivolumab as a single agent as recommended in Full Prescribing Information for nivolumab. (2.2)
* Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer: YERVOY 1 mg/kg intravenously over 30 minutes immediately following nivolumab 3 mg/kg intravenously over 30 minutes on the same day, every 3 weeks for 4 doses. After completing 4 doses of the combination, administer nivolumab as a single agent as recommended in Full Prescribing Information for nivolumab. (2.2)
* Hepatocellular Carcinoma: YERVOY 3 mg/kg intravenously over 30 minutes immediately following nivolumab 1 mg/kg intravenously over 30 minutes on the same day, every 3 weeks for 4 doses. After completing 4 doses of the combination, administer nivolumab as a single agent as recommended in Full Prescribing Information for nivolumab. (2.2)
* Metastatic non-small cell lung cancer:
* YERVOY 1 mg/kg every 6 weeks with nivolumab 360 mg every 3 weeks. (2.2)
* YERVOY 1 mg/kg every 6 weeks with nivolumab 360 mg every 3 weeks and 2 cycles of platinum-doublet chemotherapy. (2.2)

* Malignant pleural mesothelioma: YERVOY 1 mg/kg every 6 weeks with nivolumab 360 mg every 3 weeks. (2.2)
* Esophageal squamous cell carcinoma: YERVOY 1 mg/kg every 6 weeks with nivolumab 3 mg/kg every 2 weeks or 360 mg every 3 weeks. (2.2)
* See full Prescribing Information for preparation and administration instructions and dosage modifications for adverse reactions.

Get Your Patient on Yervoy

See your patient's specific prior authorization requirements including coverage restrictions and step therapies

Or select your Insurance from the list below:

Yervoy Prescribing Information

Contact Medical Science Liaison

Report Adverse Event

Yervoy Prior Authorization Resources

Most recent state uniform prior authorization forms

Verified: Sep 24, 2024Arizona - Uniform Prior Authorization Form

Verified: Sep 24, 2024Colorado - Uniform Prior Authorization Form

Verified: Sep 24, 2024Hawaii - Uniform Prior Authorization Form

Verified: Sep 24, 2024Illinois - Uniform Prior Authorization Form

Verified: Sep 24, 2024Indiana - Uniform Prior Authorization Form

Verified: Sep 24, 2024Louisiana - Uniform Prior Authorization Form

Verified: Sep 24, 2024Minnesota - Uniform Prior Authorization Form

Verified: Sep 24, 2024New Hampshire - Uniform Prior Authorization Form

Verified: Sep 24, 2024New Mexico - Uniform Prior Authorization Form

Verified: Sep 24, 2024Oregon - Uniform Prior Authorization Form

Verified: Sep 24, 2024Texas - Uniform Prior Authorization Form

Verified: Oct 05, 2024Washington - Uniform Prior Authorization Form

Verified: Oct 05, 2024Wisconsin - Uniform Prior Authorization Form

Commercial Claim Denial Appeal/Redetermination Letter

Coverage Authorization Appeals

Complete Letter of Medical Necessity

Medically Unlikely Edit (MUE) Appeal Letter

Benefits investigation

Yervoy Enrollment Form

Yervoy Enrollment Form - Spanish

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information

Yervoy Preferred Pharmacy

Pharmacy List